Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomised, Open-labeled, Parallel Group Study to Assess the Effect of Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI

NCT04338919 is registered in ClinicalTrials.gov with Fujian Medical University as lead sponsor.

NCT NCT04338919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04338919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomised, Open-labeled, Parallel Group Study to Assess the Effect of Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI
Lead sponsor
Fujian Medical University
Phase
Not applicable
Overall status
Unknown status
Start date
April 14, 2020
Completion date
April 1, 2023
Enrollment
2,020 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, percutaneous coronary intervention